| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FIMMU.2018.00969 |
| P8608 | Fatcat ID | release_n3ol57dluzc2hpquouso3j6vdu |
| P932 | PMC publication ID | 5949565 |
| P698 | PubMed publication ID | 29867951 |
| P50 | author | Marko Radic | Q57542832 |
| P2093 | author name string | Debendra Pattanaik | |
| P2860 | cites work | Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 |
| Extracellular DNA traps promote thrombosis. | Q24613579 | ||
| Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant | Q24633473 | ||
| Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome | Q27620388 | ||
| Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome | Q47311173 | ||
| HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. | Q47677888 | ||
| Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. | Q48065124 | ||
| Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. | Q48074369 | ||
| Familial anticardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. | Q49185648 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Activation of mTOR is involved in anti-β2GPI/β2GPI-induced expression of tissue factor and IL-8 in monocytes. | Q52567143 | ||
| NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. | Q53063239 | ||
| A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. | Q53598537 | ||
| PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. | Q53609970 | ||
| Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. | Q54073056 | ||
| Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. | Q54599187 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. | Q55239351 | ||
| Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance | Q57186231 | ||
| Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome | Q57624160 | ||
| Major histocompatibility complex associations with primary antiphospholipid syndrome | Q58143748 | ||
| Neutrophil extracellular traps kill bacteria | Q27860996 | ||
| HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus | Q28138464 | ||
| Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules | Q28213303 | ||
| Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab | Q28260452 | ||
| Eculizumab and renal transplantation in a patient with CAPS | Q28281405 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus | Q28365920 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Neutrophil recruitment and function in health and inflammation | Q29616689 | ||
| Histone deimination as a response to inflammatory stimuli in neutrophils. | Q30367246 | ||
| Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. | Q30497721 | ||
| Neutrophil extracellular traps: is immunity the second function of chromatin? | Q30524665 | ||
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome | Q33341518 | ||
| E-Selectin mediates pathogenic effects of antiphospholipid antibodies | Q33349081 | ||
| The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus | Q33360375 | ||
| Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome | Q33369548 | ||
| Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies | Q33384065 | ||
| Non-criteria manifestations of antiphospholipid syndrome | Q33388991 | ||
| High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus | Q33455163 | ||
| A family study of anticardiolipin antibodies and associated clinical conditions | Q33487561 | ||
| Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW x BXSB) F1 mice | Q33503790 | ||
| Thrombosis: tangled up in NETs | Q33556910 | ||
| Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. | Q33576496 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. | Q33796355 | ||
| The role of neutrophils and NETosis in autoimmune and renal diseases | Q33904653 | ||
| Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. | Q33948737 | ||
| Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells | Q33950104 | ||
| Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. | Q33967600 | ||
| The neutrophil as a cellular source of chemokines | Q34118783 | ||
| Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. | Q34296850 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope | Q58895662 | ||
| Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets | Q59065667 | ||
| Toll-like receptor 4 and β2 glycoprotein I interaction on endothelial cells | Q60547104 | ||
| Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia | Q61415575 | ||
| Human Cytomegalovirus Induces Systemic Immune Activation Characterized by a Type 1 Cytokine Signature | Q61863439 | ||
| Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups | Q61943923 | ||
| Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. | Q64966940 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss | Q68528823 | ||
| Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies | Q71613866 | ||
| Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction) | Q72190106 | ||
| HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients | Q73395887 | ||
| Blebs and apoptotic bodies are B cell autoantigens | Q74334880 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome | Q78124733 | ||
| A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice | Q79869726 | ||
| The antiphospholipid syndrome | Q79870443 | ||
| The placental bed in pregnancies complicated by primary antiphospholipid syndrome | Q80349512 | ||
| Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation | Q80851651 | ||
| TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss | Q81178348 | ||
| Complement activation in patients with primary antiphospholipid syndrome | Q81638094 | ||
| Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view | Q83954324 | ||
| Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS) | Q84212281 | ||
| Phagocytosis of platelet microvesicles and beta2- glycoprotein I | Q84388641 | ||
| The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study | Q84438431 | ||
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| Cellular signaling by antiphospholipid antibodies | Q87418426 | ||
| Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma | Q87506720 | ||
| MHC Class II Alleles influence Induction of Pathogenic Antiphospholipid Antibodies in a Thrombosis Mouse Model | Q38699947 | ||
| Pathogenesis and management of antiphospholipid syndrome | Q39198671 | ||
| In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis | Q39328138 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept | Q40002234 | ||
| Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice | Q40087226 | ||
| Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. | Q41084661 | ||
| Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. | Q41818166 | ||
| Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target | Q42162703 | ||
| V gene analysis of anticardiolipin antibodies from MRL-lpr/lpr mice | Q42799873 | ||
| Residues that mediate DNA binding of autoimmune antibodies | Q42799912 | ||
| Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. | Q43984230 | ||
| Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster | Q44189585 | ||
| Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies | Q44305352 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice | Q45105184 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism | Q45857473 | ||
| Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia | Q47105114 | ||
| Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome | Q47116452 | ||
| Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. | Q47233334 | ||
| Emerging concepts in the molecular pathogenesis of systemic lupus erythematosus | Q34578430 | ||
| Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines | Q35000251 | ||
| Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice | Q35070716 | ||
| β2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies | Q35126642 | ||
| Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis | Q35214636 | ||
| Pathophysiology of the antiphospholipid antibody syndrome | Q35309024 | ||
| Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation | Q35778578 | ||
| Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. | Q35844573 | ||
| Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. | Q35854768 | ||
| Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome | Q35874202 | ||
| Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. | Q35895238 | ||
| The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse | Q35909733 | ||
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial | Q36139749 | ||
| Current trends in drug-induced autoimmunity | Q36180084 | ||
| Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus | Q36227184 | ||
| Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction | Q36228832 | ||
| Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics | Q36329966 | ||
| Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? | Q36785674 | ||
| Antiphospholipid syndrome (APS): where does it come from? | Q37027969 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms | Q37249524 | ||
| Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway | Q37349421 | ||
| Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? | Q37547996 | ||
| Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome | Q37585221 | ||
| The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis | Q37721612 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. | Q37903952 | ||
| Pathophysiology of thrombotic APS: where do we stand? | Q38013582 | ||
| The protein arginine deiminases: Structure, function, inhibition, and disease. | Q38061870 | ||
| From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome | Q38130022 | ||
| Citrullination of autoantigens implicates NETosis in the induction of autoimmunity. | Q38167579 | ||
| Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis | Q38177962 | ||
| Clearance of Apoptotic Bodies, NETs, and Biofilm DNA: Implications for Autoimmunity | Q38240144 | ||
| Citrullinated Autoantigens: From Diagnostic Markers to Pathogenetic Mechanisms. | Q38263755 | ||
| Vasculitis in antiphospholipid syndrome | Q38268555 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | thrombosis | Q261327 |
| globulins | Q321710 | ||
| cell | Q7868 | ||
| blood proteins | Q425056 | ||
| antiphospholipid syndrome | Q582207 | ||
| P304 | page(s) | 969 | |
| P577 | publication date | 2018-05-07 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome | |
| P478 | volume | 9 |
| Q94683713 | COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies? |
| Q64981840 | Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. |
| Q91868696 | Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome |
| Q90230532 | Structural and functional characterization of β2 -glycoprotein I domain 1 in anti-melanoma cell migration |
| Q60961044 | β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease |
Search more.